These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 33812973

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. L-type Amino Acid Transporter 1 Utilizing Ferulic Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas Along with Decreased Lipid Peroxidation and Prostaglandin Production.
    Tampio J, Markowicz-Piasecka M, Montaser A, Rysä J, Kauppinen A, Huttunen KM.
    Mol Pharm; 2022 Nov 07; 19(11):3806-3819. PubMed ID: 36027044
    [Abstract] [Full Text] [Related]

  • 24. NO-NSAIDs. Part 3: nitric oxide-releasing prodrugs of non-steroidal anti-inflammatory drugs.
    Borhade N, Pathan AR, Halder S, Karwa M, Dhiman M, Pamidiboina V, Gund M, Deshattiwar JJ, Mali SV, Deshmukh NJ, Senthilkumar SP, Gaikwad P, Tipparam SG, Mudgal J, Dutta MC, Burhan AU, Thakre G, Sharma A, Deshpande S, Desai DC, Dubash NP, Jain AK, Sharma S, Nemmani KV, Satyam A.
    Chem Pharm Bull (Tokyo); 2012 Nov 07; 60(4):465-81. PubMed ID: 22466730
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
    Kärkkäinen J, Gynther M, Kokkola T, Petsalo A, Auriola S, Lahtela-Kakkonen M, Laine K, Rautio J, Huttunen KM.
    Int J Pharm; 2018 Jun 10; 544(1):91-99. PubMed ID: 29669256
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line.
    Takahashi Y, Nishimura T, Higuchi K, Noguchi S, Tega Y, Kurosawa T, Deguchi Y, Tomi M.
    Pharm Res; 2018 Oct 29; 35(12):246. PubMed ID: 30374619
    [Abstract] [Full Text] [Related]

  • 29. Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands.
    Huttunen J, Agami M, Tampio J, Montaser AB, Huttunen KM.
    Molecules; 2021 Dec 22; 27(1):. PubMed ID: 35011270
    [Abstract] [Full Text] [Related]

  • 30. L-Type amino acid transporter 1 as a target for drug delivery.
    Puris E, Gynther M, Auriola S, Huttunen KM.
    Pharm Res; 2020 May 06; 37(5):88. PubMed ID: 32377929
    [Abstract] [Full Text] [Related]

  • 31. The Multifaceted Role of L-Type Amino Acid Transporter 1 at the Blood-Brain Barrier: Structural Implications and Therapeutic Potential.
    Ahmed HS.
    Mol Neurobiol; 2024 Sep 26. PubMed ID: 39325101
    [Abstract] [Full Text] [Related]

  • 32. Characteristics of L-citrulline transport through blood-brain barrier in the brain capillary endothelial cell line (TR-BBB cells).
    Lee KE, Kang YS.
    J Biomed Sci; 2017 May 10; 24(1):28. PubMed ID: 28490336
    [Abstract] [Full Text] [Related]

  • 33. Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen.
    Huttunen KM.
    Bioorg Chem; 2018 Dec 10; 81():494-503. PubMed ID: 30243240
    [Abstract] [Full Text] [Related]

  • 34. Sodium-Dependent Neutral Amino Acid Transporter 2 Can Serve as a Tertiary Carrier for l-Type Amino Acid Transporter 1-Utilizing Prodrugs.
    Huttunen J, Kronenberger T, Montaser AB, Králová A, Terasaki T, Poso A, Huttunen KM.
    Mol Pharm; 2023 Feb 06; 20(2):1331-1346. PubMed ID: 36688491
    [Abstract] [Full Text] [Related]

  • 35. Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents.
    Huttunen J, Gynther M, Huttunen KM.
    Int J Pharm; 2018 Oct 25; 550(1-2):278-289. PubMed ID: 30149128
    [Abstract] [Full Text] [Related]

  • 36. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
    Bhunia S, Vangala V, Bhattacharya D, Ravuri HG, Kuncha M, Chakravarty S, Sistla R, Chaudhuri A.
    Mol Pharm; 2017 Nov 06; 14(11):3834-3847. PubMed ID: 28958145
    [Abstract] [Full Text] [Related]

  • 37. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.
    Ylikangas H, Peura L, Malmioja K, Leppänen J, Laine K, Poso A, Lahtela-Kakkonen M, Rautio J.
    Eur J Pharm Sci; 2013 Feb 14; 48(3):523-31. PubMed ID: 23228412
    [Abstract] [Full Text] [Related]

  • 38. Aminopeptidase B can bioconvert L-type amino acid transporter 1 (LAT1)-utilizing amide prodrugs in the brain.
    Hugele A, Löffler S, Molina BH, Guillon M, Montaser AB, Auriola S, Huttunen KM.
    Front Pharmacol; 2022 Feb 14; 13():1034964. PubMed ID: 36339537
    [Abstract] [Full Text] [Related]

  • 39. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A, Ottani A, Sandrini M.
    Pharmacol Res; 2001 Dec 14; 44(6):437-50. PubMed ID: 11735348
    [Abstract] [Full Text] [Related]

  • 40. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.
    Gynther M, Peura L, Vernerová M, Leppänen J, Kärkkäinen J, Lehtonen M, Rautio J, Huttunen KM.
    Neurochem Res; 2016 Oct 14; 41(10):2797-2809. PubMed ID: 27412117
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.